IL37 and non-small cell lung carcinoma: Our results indicate that HDAC inhibitors may not be a viable therapeutic treatment option in NSCLC, at least as a single entity given that in our experience, both SAHA and TSA increase the expression of both IL-23 and IL-23R levels.